Biotechnology News and Research

RSS

DNA modification can define early onset glioblastoma

A class of brain tumor that tends to emerge in younger patients but is less aggressive than others can be identified by examining DNA methylation of a specific set of genes, scientists at The University of Texas M. D. Anderson Cancer Center and colleagues with The Cancer Genome Atlas report today online at Cancer Cell.

16 Apr 2010

Promising pharmacokinetic data from Idenix Pharmaceuticals' Phase I study of IDX320 for HCV

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported promising in vitro data for IDX320, an HCV protease inhibitor, demonstrating potent and selective antiviral activity in multiple genotypes, or strains, of the virus.

16 Apr 2010

Study: Circadian’s anti-cancer therapy reduces tumour growth in animal models

Circadian Technologies Limited today released data demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth in a variety of different animal models (tumour xenografts) of human cancer.

16 Apr 2010

Celsion announces presentation of long-term follow-up data from Phase I ThermoDox dose escalation trial

Celsion Corporation today announced that Dr. Ronnie T.P. Poon, a principal investigator of the Phase I ThermoDox® dose escalation trial, held a press conference at the University of Hong Kong to provide an update on the long-term follow-up data from patients treated at his center as well as present illustrative patient case studies. The Phase I trial was conducted in 2006.

16 Apr 2010

Flavonoids of onion are natural alternative to artificial additives in food industry: Study

Some components of the onion have antioxidant and antimicrobial properties, making it possible to use this bulb for food preservation. This is demonstrated by researchers from the Polytechnic University of Catalu-a and the University of Barcelona in a study that has just been published in the International Journal of Food Science and Technology.

16 Apr 2010

Sunlight Research's Stem Cell Industry Report analyzes U.S. Stem Cell patent landscape

Sunlight Research – The Source for Patent Analysis, today announced the release of its comprehensive Stem Cell Industry Report analyzing the U.S. Stem Cell patent landscape. Stem cells are particularly attractive for use as cellular therapies because they self-renew and have the capacity to produce many different specialized cell types.

16 Apr 2010

Results from Romark Laboratories' STEALTH C-3 clinical trial presented at EASL Annual Meeting

Romark Laboratories announced results from its STEALTH C-3 clinical trial, a phase 2 clinical study of nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C. Study results were presented as a late breaking communication at the International Liver Congress™ 2010, the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Austria.

16 Apr 2010

Idaho Technology receives USASMDC contract to develop flu tests for military personnel

Idaho Technology, Inc. has been awarded a contract by the U.S. Army Space and Missile Defense Command (USASMDC) to develop tests for multiple flu strains on the Joint Biological Agent Identification and Diagnostic System (JBAIDS).

16 Apr 2010

PPA helps qualified patients save money on their medicines

As recently noted in the Queens Chronicle, a nationwide partnership, consisting of more than 475 public and private assistance programs, is helping qualified patients save money on their medicines.

16 Apr 2010

LOTS results of Myozyme in older children and adults with Pompe disease published

Genzyme Corp. today announced that the results from its Late-Onset Treatment Study have been published in today's New England Journal of Medicine. The study was undertaken to evaluate the safety and efficacy of Myozyme (alglucosidase alfa) in older children and adults with Pompe disease.

16 Apr 2010

Boston Scientific receives FDA clearance to resume distribution of COGNIS CRT-Ds and TELIGEN ICDs

Boston Scientific Corporation today announced that it has received U.S. Food and Drug Administration clearance for the two validated manufacturing changes affecting all of its cardiac resynchronization therapy defibrillators and implantable cardioverter defibrillators, and that it will immediately resume distribution of its COGNIS CRT-Ds and TELIGEN ICDs.

16 Apr 2010

Nottingham and Japanese scientists to study genetic variation of E. coli bacteria

University of Nottingham scientists will join forces with Japan in the fight against a common bacterium - thanks to an international research award.

16 Apr 2010

3M Drug Delivery Systems grows its product portfolio in Asia’s pharmaceutical industry

3M Drug Delivery Systems recently advanced its participation in the Asian market with a sponsorship of the Asia Pharma R&D Leaders 2010 event, held March 4 and 5 in Shanghai, China.

16 Apr 2010

Vertex Pharmaceuticals announces results from Phase 1b clinical trial of VX-222

In conjunction with an oral presentation at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Vertex Pharmaceuticals Incorporated today announced results from a Phase 1b clinical trial of the investigational oral hepatitis C virus polymerase inhibitor, VX-222. In the trial, treatment with VX-222 for three days was well-tolerated, with all adverse events being mild to moderate in severity.

16 Apr 2010

Albert Einstein College of Medicine of Yeshiva University receives funds to expand stem cell research capabilities

Albert Einstein College of Medicine of Yeshiva University has been awarded $10 million from the National Institutes of Health to expand its stem cell research capabilities. The funds will be used to create new laboratories in order to increase its already substantial base of stem cell investigators.

16 Apr 2010

sBioMed's anthrax killing sterilant receives EPA approval

It has been nine years since the 2001 anthrax attacks sickened twenty-three people and killed five. Since that time, the U.S. government has spent hundreds of millions of dollars in remediation and billions in their search for a disinfectant that can reliably kill anthrax spores and other pathogens that might be used as weapons.

16 Apr 2010

Advaxis initiates Phase 2 clinical trial of ADXS11-001 for treatment of CIN

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, initiated the Company's first clinical trial site in its randomized, single blind, placebo-controlled, Phase 2 clinical trial of ADXS11-001 for the treatment of cervical intraepithelial neoplasia.

16 Apr 2010

Takeda Pharmaceutical offers milestone payment to XOMA

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced it has received a $1 million milestone payment from Takeda Pharmaceutical Company Limited for achieving a pre-established preclinical milestone under the companies' 2006 collaboration agreement, which also calls for additional future milestone payments and royalties on product sales.

16 Apr 2010

High sensitivity of Zetasizer Nano proves essential for protein aggregation studies

Dr Martin Muschol, Assistant Professor at the University of South Florida’s (USF) Department of Physics and his team are carrying out important research to gain a better understanding of protein aggregation phenomena, including protein crystallization and amyloid fibril growth. Using the Zetasizer Nano ZS, from Malvern Panalytical (Malvern Panalytical, UK), the USF researchers have been able to perform temperature controlled static and dynamic light scattering (DLS) measurements of protein hydration, protein interactions and aggregation kinetics in vitro.

From Malvern Panalytical 15 Apr 2010

Celgene, Agios Pharmaceuticals form global strategic collaboration on targeting cancer metabolism

Celgene Corporation and Agios Pharmaceuticals Inc., a privately-held biotechnology company, today announced the formation of a global strategic collaboration focused on targeting cancer metabolism. The goal of the collaboration is to discover, develop, and deliver novel disease-altering therapies in oncology based on the transformational science of Agios' innovative cancer metabolism research platform. This platform is based on the concept that targeting key metabolic enzymes unique to rapidly proliferating cancer cells can "starve" the cancer.

15 Apr 2010

Biotechnology News and Research

DNA modification can define early onset glioblastoma

Promising pharmacokinetic data from Idenix Pharmaceuticals' Phase I study of IDX320 for HCV

Study: Circadian’s anti-cancer therapy reduces tumour growth in animal models

Celsion announces presentation of long-term follow-up data from Phase I ThermoDox dose escalation trial

Flavonoids of onion are natural alternative to artificial additives in food industry: Study

Sunlight Research's Stem Cell Industry Report analyzes U.S. Stem Cell patent landscape

Results from Romark Laboratories' STEALTH C-3 clinical trial presented at EASL Annual Meeting

Idaho Technology receives USASMDC contract to develop flu tests for military personnel

PPA helps qualified patients save money on their medicines

LOTS results of Myozyme in older children and adults with Pompe disease published

Boston Scientific receives FDA clearance to resume distribution of COGNIS CRT-Ds and TELIGEN ICDs

Nottingham and Japanese scientists to study genetic variation of E. coli bacteria

3M Drug Delivery Systems grows its product portfolio in Asia’s pharmaceutical industry

Vertex Pharmaceuticals announces results from Phase 1b clinical trial of VX-222

Albert Einstein College of Medicine of Yeshiva University receives funds to expand stem cell research capabilities

sBioMed's anthrax killing sterilant receives EPA approval

Advaxis initiates Phase 2 clinical trial of ADXS11-001 for treatment of CIN

Takeda Pharmaceutical offers milestone payment to XOMA

High sensitivity of Zetasizer Nano proves essential for protein aggregation studies

Celgene, Agios Pharmaceuticals form global strategic collaboration on targeting cancer metabolism

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News